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Farnesyltransferase inhibitors (FTIs) block Ras farne-
sylation, subcellular localization and activity, and in-
hibit the growth of Ras-transformed cells. Although
FTIs are ineffective against K-Ras4B, the Ras isoform
most commonly mutated in human cancers, they can
inhibit the growth of tumors containing oncogenic
K-Ras4B, implicating other farnesylated proteins or
suggesting distinct functions for farnesylated and for
geranylgeranylated K-Ras, which is generated when far-
nesyltransferase is inhibited. In addition to bypassing
FTI blockade through geranylgeranylation, K-Ras4B re-
sistance to FTIs may also result from its higher affinity
for farnesyltransferase. Using chimeric Ras proteins
containing all combinations of Ras background, CAAX
motif, and K-Ras polybasic domain, we show that either
a polybasic domain or an alternatively prenylated CAAX
renders Ras prenylation, Ras-induced Elk-1 activation,
and anchorage-independent cell growth FTI-resistant.
The polybasic domain alone increases the affinity of Ras
for farnesyltransferase, implying independent roles for
each K-Ras4B sequence element in FTI resistance. Using
microarray analysis and colony formation assays, we
confirm that K-Ras function is independent of the iden-
tity of the prenyl group and, therefore, that FTI inhibi-
tion of K-Ras transformed cells is likely to be independ-
ent of K-Ras inhibition. Our results imply that relevant
FTI targets will lack both polybasic and potentially
geranylgeranylated methionine-CAAX motifs.
The four human Ras proteins (H-Ras, N-Ras, K-Ras4A, and
K-Ras4B) are small GTP-binding proteins that are found at the
inner leaflet of the plasma membrane, have intrinsic GTPase
activity, and play a central role in signaling such diverse cel-
lular responses as proliferation, differentiation, motility, and
apoptosis. Ras mutations that reduce or eliminate its inherent
GTPase function (typically at position 12, 13, or 61) lead to
constitutive GTP binding and activation and are associated
with 30% of human tumors (1). Not surprisingly, inhibition of
Ras function has become the focus of numerous anti-cancer
drug development efforts. One such effort has been the devel-
opment of pharmacological inhibitors of farnesyltransferase
(FTase),1 the enzyme that catalyzes the obligate first step in a
series of post-translational modifications of Ras that are collec-
tively required for Ras to localize to the plasma membrane,
where it is biologically active (2). The COOH-terminal four
amino acids, collectively called the “CAAX” motif, are sufficient
to initiate the modification of Ras by FTase. The CAAX motif
includes a conserved cysteine (C), two aliphatic residues (AA)
and any other amino acid (X). FTase catalyzes the covalent
addition of a 15-carbon farnesyl isoprenoid to the cysteine
residue of the CAAX motif. This isoprenylation step is followed
by proteolytic removal of the -AAX sequence and carboxy-
methylation of the resulting carboxyl terminus. Finally, in the
case of H-Ras, N-Ras, and K-Ras4A, one (N-Ras) or two (H-Ras
and K-Ras4A) cysteine residues just upstream from the CAAX
motif become palmitoylated. K-Ras4B is not palmitoylated and
instead contains a stretch of six consecutive lysine residues
(the polybasic domain, “K6”) in place of the palmitoylatable
cysteines and surrounding residues. Similar post-translational
modifications occur on a relatively small set of other farnesyl-
ated cellular proteins, not all of which have been identified
or characterized.
FTase inhibitors (FTIs) have now been studied extensively
(3, 4). In preclinical studies (5, 6), FTIs inhibited farnesylation
of H-Ras in vitro and in vivo, blocked H-Ras signaling and
transformation, inhibited cell cycle progression in human tu-
mor cell lines, and induced regression of mammary and sali-
vary tumors in H-Ras transgenic mice and lymphoid tumors in
N-Ras transgenic mice. Moreover, FTIs preferentially induce
apoptosis and increase radiosensitivity in transformed cells
and show additive or synergistic effects with standard cancer
chemotherapies, especially taxanes. Although Ras is required
for normal cell cycle progression, FTIs selectively block trans-
formed cell growth compared with normal cells and interfere
with signaling from oncogenic Ras but not from growth factors
that require endogenous Ras function. This selectivity, al-
though surprising, allayed initial fears that the clinical utility
of FTIs might be limited by grossly toxic effects on nontrans-
formed cells. Several FTIs are currently in clinical trials as
cancer treatments.
Although they were originally designed to be anti-Ras drugs,
and although they effectively inhibit H-Ras signaling and
transformation, FTIs do not block either the processing or the
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function of K-Ras4B (7), the isoform of Ras most frequently
mutated in human tumors. Instead, in the presence of FTIs,
K-Ras can become prenylated by the FTase-related enzyme
geranylgeranyltransferase I (GGTase I) (8, 9) by virtue of a
CAAX motif in which X is methionine (an M-CAAX). Neverthe-
less, FTI treatment can significantly inhibit the growth of
tumors containing mutated K-Ras4B (10–12). This indicates
either that farnesylated proteins other than Ras must also play
a role in the biological consequences of FTI treatment (13) or
that farnesylated and geranylgeranylated K-Ras function dif-
ferently. Other farnesylated proteins that may be important
FTI targets include the Ras-related protein RhoB (14, 15), the
centromere-binding proteins CenP-E and CenP-F (16, 17), the
phosphatases PRL1, -2, and -3 (18), and nuclear lamins (19),
but no protein yet identified can explain all of the actions
of FTIs.
As it becomes increasingly clear that farnesylated proteins
other than Ras are important FTI targets, it also becomes
important to define clearly the mechanisms by which K-Ras
FTI resistance is conferred and to identify unambiguously the
K-Ras sequence elements that are involved. K-Ras resistance
to FTI is the result of two distinct mechanisms. The first is
alternative prenylation by GGTase which allows K-Ras to by-
pass the FTI block. The second results from K-Ras having a
higher affinity for FTase than does H-Ras or N-Ras (20, 21),
making it more difficult for peptidomimetic FTIs to compete
with K-Ras for FTase binding. That only K-Ras has both in-
creased FTase affinity and a polybasic domain suggests that
the polybasic domain, but not the M-CAAX common to N- and
K-Ras, contributes significantly to the Ras/FTase interaction.
However, James et al. (20) observed that neither an M-CAAX
nor a polybasic domain was able by itself to increase Ras FTase
affinity or the resistance of H-Ras to a benzodiazepine FTI.
In order to resolve this discrepancy, further define the rela-
tive contributions of each Ras sequence element to Ras/FTase
association and K-Ras FTI resistance, and develop more strin-
gent criteria for identifying other farnesylated protein targets
of FTI, we generated a comprehensive set of activated Ras
mutants, consisting of all combinations of Ras background (H-,
N-, and K-Ras4B), CAAX motif (-CVLS, -CVVM, and -CVIM),
and polybasic domain (with or without). We then assessed their
sensitivity to FTI with respect to alterations in Ras prenylation
status, Ras-induced Elk-1 activation, and Ras-induced anchor-
age-independent cell growth. We show that the polybasic do-
main and the CAAX motif contribute individually to the resist-
ance of K-Ras4B to the FTI L-744,832. We propose, in contrast
to previous reports, that the polybasic domain alone confers
partial FTI resistance by increasing the affinity of K-Ras4B for
FTase, thereby rendering FTIs less effective as competitive
inhibitors, whereas the M-CAAX motif acts primarily by pro-
moting alternative prenylation in the presence of FTI. Finally,
we also provide confirmation of the notion that FTI inhibition
of the Ras-mediated transformed phenotype results in part
from functional inhibition of farnesylated proteins other than
Ras. These data have implications for understanding the mech-
anism of FTI inhibition of tumor growth.
EXPERIMENTAL PROCEDURES
Generation of Ras Mutants—Ras constructs were generated by PCR
using primers (University of North Carolina Lineberger Comprehen-
sive Cancer Center Nucleic Acids Core Facility) coding for the desired
mutant COOH-terminal sequence (Fig. 1). Parental oncogenic H-, N-,
and K-Ras4B coding sequences (H-Ras (61L), N-Ras (12D), and K-Ras
(12V)) were used as PCR templates in order to generate constitutively
active Ras proteins as described (22). Primers were also designed to
generate restriction sites (SalI at the 5-end of the coding sequence,
BamHI at the 3-end) for directional insertion into the mammalian
expression vector, pDCR, in frame with the coding sequence for the
hemagglutinin (HA) tag. After amplification, PCR products were puri-
fied and digested with SalI and BamHI, extracted with phenol/chloro-
form, and ethanol-precipitated. pDCR was treated similarly. Insert was
ligated into vector and transformed into competent Escherichia coli
strain DH5. Plasmid sequences were confirmed prior to use by auto-
mated sequencing (University of North Carolina Automated DNA Se-
quencing Facility). Protein expression was driven by the cytomegalov-
irus promoter of pDCR and confirmed by Western analysis using
anti-HA antibody MonoHA (BAbCo, Richmond, CA). Some mutants
were also inserted into the mammalian expression vector pZ-
IPneoSV(X)1 (22).
Cell Culture and Generation of Cell Lines Stably Expressing Ras
Mutant Constructs—NIH 3T3 fibroblasts were maintained in a humid-
ified atmosphere at 37 °C in DMEM-H (Invitrogen) with 10% Colorado
Calf Serum (Colorado Serum Company, Denver, CO) and antibiotics.
Cells (plated at 5  105/60-mm dish on the day before transfection) were
transfected with 50–100 ng of pDCR-Ras by calcium phosphate precip-
itation as described previously (23). Briefly, plasmid DNA was precip-
itated with high molecular weight carrier DNA (calf thymus DNA,
Roche Applied Science) in 125 mM calcium phosphate and layered onto
cells for 3–5 h. Cells were washed, shocked in 15% glycerol for 3 min,
and returned to complete medium without selection for 48 h. Cells were
then passaged into selective antibiotic (750 g of active G418 per ml)
and fed regularly with fresh G418. Colonies appeared after 2 weeks,
and 40–70 individual colonies were pooled for use. Protein expression
was confirmed by SDS-PAGE and Western analysis on cell lysates
using antibodies directed to the HA epitope tag (BAbCo) or to Ras
(pan-Ras antibody (Ras11), catalog no. OP-40; Calbiochem).
Gel Shift Assays—The sensitivity of mutant Ras proteins to FTI-
induced inhibition of prenylation was evaluated by gel shift assay as
described (24), based on the observation that prenylated Ras proteins
migrate in SDS-PAGE more rapidly than their unprenylated counter-
parts. NIH 3T3 fibroblasts (1  105 cells/35-mm dish) were transiently
transfected with H-, N-, or K-Ras4B mutant constructs as described
above. Immediately after glycerol shock, cells were returned to com-
plete medium for 48 h in the presence of a 3 or 10 M concentration of
the FTI L-744,832 (Biomol; a kind gift from Jay Gibbs and Allen Oliff
(Merck)) or FTI-277 (Calbiochem; a kind gift from Saı̈d Sebti (Univer-
sity of South Florida) and Andy Hamilton (Yale)) or of vehicle (Me2SO
or Me2SO plus 10 M dithiothreitol, respectively). These two FTIs are
structurally distinct CAAX peptidomimetics that are competitive with
the Ras protein. Both were used throughout the study with equivalent
results. We have also performed some of these studies with a variety of
other CAAX-competitive FTI structures (including SCH 66336 (25) a
kind gift from Robert Bishop and Paul Kirschmeier, Schering-Plough),
again with similar results. Cells were washed with PBS and lysed in
500 l of 1 SDS-PAGE sample buffer per dish. Thirty microliters of
each lysate were separated by SDS-PAGE, transferred to Immobilon
polyvinylidene difluoride membranes (Fisher) and subjected to Western
analysis using anti-HA antibodies to identify only the exogenously
expressed mutant Ras proteins.
Luciferase Assays—The FTI sensitivity of mutant Ras signaling
through the transcription factor Elk-1 was assessed by luciferase re-
porter assay. NIH 3T3 cells (2  105 cells/35-mm dish) were transiently
transfected by calcium phosphate precipitation in duplicate with 100 ng
of the appropriate Ras mutant construct, 250 ng of a Gal-Elk-1 reporter
plasmid, and 2.5 g of 5Gal-Luciferase plasmid as described (26).
Immediately after glycerol shock, cells were returned to complete me-
dium containing various concentrations of FTI. After 48 h, cells were
washed twice with PBS, pH 7.2, lysed, and assayed for luciferase
activity using reagents from the enhanced luciferase assay kit (PharM-
ingen, San Diego, CA) according to the manufacturer’s protocols. Raw
data from duplicate samples were averaged and expressed as percent-
age of luciferase activity compared with vehicle-treated cells. All assays
were performed at least three times, and data are displayed  S.D.
Soft Agar Assays—The ability of cells to grow in the absence of
attachment to substrate is one of the hallmarks of a transformed
phenotype and can be induced by oncogenically mutated H-, N-, or
K-Ras. To determine the sensitivity of anchorage-independent growth
to FTI treatment, NIH 3T3 fibroblasts stably transfected with constructs
encoding H-, N-, or K-Ras4B mutants were removed from dishes by
trypsinization and triturated to ensure a single-cell suspension. After
counting, cells were plated in soft agar as described previously (23) in the
presence or absence of 3 or 10 M FTI or vehicle. Briefly, 1  104 cells/
35-mm dish were plated in 0.4% agar over a bottom layer of 0.6% agar.
Both layers contained 1 DMEM-H, 10% serum, antibiotics, and FTI at
the indicated concentrations. Plates were incubated at 37 °C in 10% CO2
for up to 2 weeks. Cell groups containing more than four cells were
Sequence Motifs Contributing to Ras FTI Resistance 41719
considered colonies. Colony formation in FTI-treated samples was ex-
pressed as percentage of colony formation in vehicle-treated samples.
Ras/FTase Affinity Assays—To determine the affinity of Ras mutant
proteins for FTase, in vitro prenylation assays were performed. Bacte-
rially expressed, unprenylated Ras mutant proteins (1 M) were incu-
bated with [3H]farnesyl pyrophosphate (1 M final concentration; spe-
cific activity of 8–10 Ci/mmol; American Radiolabeled Chemicals, St.
Louis, MO) and recombinant FTase (50 ng) in a reaction containing 50
mM Tris, pH 7.7, 20 mM KCl, 10 mM MgCl2, 2 mM dithiothreitol, and 5
M ZnCl2. Reaction volume was 50 l. Reactions were allowed to pro-
ceed for 10 min at 30 °C and were stopped by the addition of 0.5 ml of
4% SDS. Total protein was precipitated by the addition of 0.5 ml of 30%
trichloroacetic acid. After 20 min, samples were filtered through 25-mm
glass fiber filters (Schleicher & Schuell), which bind the protein. Reac-
tion tubes were washed with 2  2 ml of 4% SDS plus 6% trichloroacetic
acid, and the washes were added to the filters. Bound protein was
washed with a further 4 ml of 4% SDS/6% trichloroacetic acid and then
3  2 ml 6% trichloroacetic acid. After drying, radioactivity bound to the
filters was quantitated in a scintillation counter. Negative controls
were also performed without protein substrate or using FTase that was
previously inactivated by incubation for 5 min at 90 °C. Each substrate
protein was reacted under standard conditions with vehicle or a range of
FTI concentrations (5–625 nM) to block the farnesylation reaction. The
level of farnesylation in FTI-treated samples was expressed as a percent-
age of maximum incorporation of [3H]farnesyl for each substrate, as
determined by allowing the uninhibited reaction to go to completion.
Growth Inhibition Assays—NIH 3T3 cells were transfected as de-
scribed above with 50 ng of plasmid containing wild-type H-, N-, or
K-Ras4B mutated to be substrates for geranylgeranylation (H-Ras-
(CVLL), N-Ras(CVVL), or K-Ras4B(CVIL) or empty vector (pZIPneo).
After 48 h, cells were passaged into G418 selection until colonies ap-
peared. Plates were washed twice in PBS, and the colonies were fixed in
methanol/acetic acid and stained with 0.4% crystal violet before
photography.
RESULTS
Design and Construction of Mutant Ras Proteins—In order to
evaluate the individual and combined contributions of either
the methionine-containing CAAX (M-CAAX) motif characteris-
tic of N-Ras and K-Ras4B or the polybasic domain (K6) unique
to K-Ras4B, we generated a comprehensive set of chimeric Ras
mutants (Fig. 1). We then evaluated the FTI sensitivity of their
prenylation status, ability to induce anchorage-independent
growth, and signaling through the transcription factor Elk-1.
In addition, the affinity of several mutants for FTase was
assessed directly. Since all mutations were near the COOH
terminus, constructs were produced by PCR using mutagenic
COOH-terminal primers. The COOH-terminal region of the
parental Ras sequences were aligned as shown in Fig. 1, and
the mutants were generated by homologous substitution be-
tween corresponding regions of each sequence. Two of the con-
structs (H-(K6) and H-(K6)-CVIM) were further modified to
remove a palmitoylatable cysteine residue at position 184. This
was done because Ras proteins normally contain, in addition to
the CAAX motif, either a palmitoylated cysteine(s) or a poly-
basic domain but not both. Without this substitution, these two
constructs would contain three potential membrane-targeting
sequences, making it difficult to determine unambiguously the
relative contributions of the CAAX motif and the polybasic
domain to FTI resistance.
The Polybasic Domain Confers FTI Resistance in the Absence
of Alternative Prenylation—The observed FTI resistance of N-
and K-Ras4B as compared with H-Ras has been attributed to
two possible mechanisms that may function in vivo separately
FIG. 1. Generation of mutant Ras
sequences. The COOH-terminal se-
quences of the parental Ras proteins and
Ras mutants are shown. All constructs
contain activating mutations and an NH2-
terminal HA tag but are otherwise iden-
tical to the corresponding wild-type Ras
proteins. Mutations were designed by ho-
mologous exchange between correspond-
ing sequences in the parental constructs
and generated by PCR using mutagenic 3
primers. The CAAX motif, polybasic do-
main, and palmitoylated cysteines are in-
dicated by boxes. The boxes in H-(K6) and
H-(K6)-CVIM indicate additional cys-
teine-to-serine mutations made to pre-
vent palmitoylation of those constructs.
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or together. First, higher affinity between K-Ras4B and FTase
may render FTIs less effective as competitive inhibitors against
this isoform (20, 21). Second, the now well established potential
for N- and K-Ras4B to become alternatively prenylated by
GGTase upon FTI-induced FTase inactivation (8, 9) presum-
ably allows these isoforms to bypass the FTI block. However,
assays designed to assess Ras function in vivo (such as soft
agar assays, focus formation assays, and transcriptional re-
porter assays) cannot by themselves distinguish between these
two possibilities. Nor can the use of wild-type Ras proteins in
such studies unambiguously identify the Ras sequence ele-
ments responsible for each mechanism. With the panel of Ras
mutants we constructed, we were able to address these points.
We first assessed the ability of FTI to block Ras prenylation
by showing a shift in gel mobility characteristic of unpreny-
lated Ras proteins compared with the prenylated forms (Fig. 2).
NIH 3T3 fibroblasts were transiently transfected with each
HA-tagged Ras construct and treated for 48 h with various
concentrations of FTI or vehicle. To ensure that effects were not
due to a particular FTI structure, we used both L-744,832 and
FTI-277 throughout most of these studies with equivalent re-
sults. Cell lysates were separated by SDS-PAGE and subjected
to Western analysis using anti-HA antibody. At steady state,
50% of parental H-Ras showed decreased gel mobility in
response to 2.5 M FTI, whereas 10 M FTI produced a com-
plete mobility shift after 48 h of treatment. These results indi-
cate that, as expected, H-Ras became unprocessed in a dose-
dependent manner in the presence of FTI. In contrast, an
H-Ras construct containing a polybasic domain (H-(K6))
showed no mobility shift at either 3 M or 10 M FTI. This
increase in FTI resistance was unlikely to result from alterna-
tive prenylation, since proteins containing a CVLS CAAX se-
quence have been shown to be poor substrates for GGTase (8,
21) and since it was resistant to the geranylgeranyltransferase
inhibitor GGTI-298 (data not shown). In one study (20), the
introduction of a polybasic domain into H-Ras (H-(K6)) was
shown to permit limited geranylgeranylation in vitro using
purified GGTase. But even with this Ras construct, farnesyla-
tion was the preferred reaction, indicating that in the presence
of both enzymes, -CVLS-containing Ras constructs are prefer-
entially farnesylated.
Similar results were obtained using N-Ras and K-Ras4B
constructs. Neither parental N-Ras nor K-Ras4B undergoes an
FTI-induced gel mobility shift even at 10 M FTI, since alter-
native geranylgeranylation results in proteins that migrate
with similar mobility as farnesylated Ras. Replacement of the
native N-Ras M-CAAX (-CVVM) with the H-Ras CAAX motif
(to generate N-CVLS) makes N-Ras susceptible to FTI-induced
gel mobility shift (80% block at 3 M FTI) (Fig. 2). Similarly,
replacement of the native K-Ras M-CAAX (-CVIM) with -CVLS,
along with replacement of the polybasic domain with a neutral
stretch of glutamines (5Q), renders K-(Q5)-CVLS susceptible to
FTI-induced inhibition of prenylation (40% block at 3 M FTI).
The subsequent addition of the polybasic domain into these
FTI-sensitive N-Ras or K-Ras constructs reduced sensitivity to
FTI-induced gel mobility shift to undetectable levels. Similarly,
introduction into FTI-sensitive K-(Q5)-CVLS of a CVIM motif
to generate K-(Q5) also resulted, as expected, in FTI resistance,
presumably through induction of alternative prenylation. The
sensitivity of K-(Q5)-CVLS to FTI and its insensitivity to GGTI
(data not shown) confirmed that this construct was not nor-
mally geranylgeranylated. Together, these data demonstrate
that the polybasic domain alone renders farnesylation of Ras
proteins partially resistant to FTI even in the absence of alter-
native prenylation. Further, that parental H-, N-, and K-Ras
proteins are not equally susceptible to FTI (50, 80, and 40%
shifts in gel mobility, respectively) suggests that sequences
outside of the CAAX motif and the polybasic domain are also
involved in FTI resistance.
The Polybasic Domain Confers FTI Resistance on H-Ras-
induced Elk-1 Activation—Unlike more complex phenotypes
such as transformation, transcriptional transactivation of a
Gal-Elk-1-luciferase reporter represents a simple system for
studying Ras-driven signaling. Further, this pathway is impor-
tant for the transformation and anchorage-independent growth
of Ras-transformed NIH 3T3 fibroblasts. Therefore, we as-
sessed the effect of the polybasic domain and M-CAAX motifs
alone and in combination on FTI resistance in H-, N-, or
FIG. 2. The polybasic domain con-
fers FTI resistance in the absence of
alternative prenylation. FTI-induced
inhibition of Ras prenylation was evalu-
ated by a gel mobility shift assay. NIH
3T3 cells were transiently transfected
with the indicated Ras constructs and
treated with vehicle or FTI. Cell lysates
were separated by SDS-PAGE and sub-
jected to Western blot analysis using an-
ti-HA antibody. Unprenylated Ras pro-
teins have decreased mobility compared
with their farnesylated counterparts.
Pren., prenylated Ras; Unpren., unpren-
ylated Ras. Representative data from at
least two independent assays are shown.
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K-Ras4B backgrounds with respect to signaling through the
transcription factor Elk-1. Each of the Ras constructs was
transiently transfected along with Elk-1-luciferase reporter
plasmids into NIH 3T3 cells that were then treated for 48 h
with various concentrations of FTI. Luciferase activity in cell
lysates reflects the ability of the transfected Ras construct to
activate Elk-1 and induce transcription from the Elk-1-depend-
ent luciferase promoter. The data presented in Fig. 3 show that
either the K-Ras4B polybasic domain or a methionine-contain-
ing CAAX motif (-CVVM or CVIM) alone can render Ras pro-
teins resistant to FTIs regardless of Ras background. Onco-
genic H-Ras with a wild-type COOH-terminal sequence is
inhibited by FTI up to 70% in a dose-dependent manner. Re-
placement of the native H-Ras CAAX motif (-CVLS) with that
of either N-Ras (-CVVM) or K-Ras4B (-CVIM) abrogates this
effect and makes H-Ras resistant to FTI at concentrations up to
8 M, presumably by permitting alternative prenylation. More
importantly, in the absence of an M-CAAX motif, the presence
of the polybasic domain also renders H-Ras resistant to FTI
(H-(K6)). This is consistent with our prenylation data (Fig. 2),
which showed increased FTI resistance of H-Ras farnesylation
when a polybasic domain is present.
The same conclusion can be drawn from the N-Ras mutants
tested (Fig. 3B). Parental N-Ras, which contains an M-CAAX,
is resistant to FTI, and this resistance is maintained even
when the native N-Ras CAAX motif (-CVVM) is replaced by the
K-Ras4B CAAX motif (-CVIM). When neither motif is present
(N-CVLS), this resistance is eliminated, and N-Ras becomes
susceptible to FTI (55% block at 8 M FTI). However, introduc-
tion of the polybasic domain into the FTI-sensitive N-Ras re-
stores FTI resistance (N-(K6)-CVLS; 0% block at 8 M). This
observation is generally consistent with the reduced ability of
FTI to prevent the prenylation of N-(K6)-CVLS (Fig. 2). To-
gether, these observations demonstrate that either motif alone
can result in the FTI resistance of Ras-dependent Elk-1
activation.
Since parental K-Ras4B contains both motifs, we predicted
that replacement of both would be necessary to render this
protein FTI-sensitive. Thus, a K-Ras4B construct in which the
polybasic domain was replaced with a series of neutral gluta-
mine residues (Q5) and containing the H-Ras CAAX motif
(-CVLS) was generated. As predicted, this construct (K-(Q5)-
CVLS) was significantly sensitive to FTI (20% block at 8 M
FTI; Fig. 3C), and this sensitivity was reversed by reintroduc-
ing either an M-CAAX (K-(Q5)-CVVM and K-(Q5)) or a polyba-
sic domain (K-CVLS). However, the FTI sensitivity of K-(Q5)-
CVLS was not nearly as pronounced as that of H-Ras or
N-CVLS (60 and 55% at 8 M FTI, respectively) although all
three lack both an M-CAAX and polybasic domain. This sug-
gests that K-Ras4B also has sequence elements outside of the
COOH-terminal region (amino acids 176–188) that contribute
to FTI resistance, probably by increasing FTase affinity. Since
such elements would have to be found only in K-Ras4B, it is
likely that they would be located NH2-terminal of the polybasic
domain but still within the region least conserved among Ras
proteins (i.e. amino acids 165–175). The fact that N-CVLS was
FIG. 3. The polybasic domain con-
fers FTI resistance on H-Ras-induced
Elk-1 activation. To determine the sen-
sitivity of mutant Ras signaling through
Elk-1, NIH 3T3 fibroblasts were tran-
siently co-transfected with Ras mutant
constructs and an Elk-1-driven luciferase
plasmid and treated with various concen-
trations of FTI or vehicle. Solid bars, ve-
hicle; light gray bars, 0.5 M FTI; dark
gray bars, 1 M FTI; open bars, 2 M FTI;
hatched bars, 4 M FTI; horizontally
striped bars, 8 M FTI. Luciferase activity
is shown as percentage of activity com-
pared with vehicle-treated cells. Samples
were evaluated in duplicate in each assay.
Data from at least three independent as-
says were averaged and are shown  S.D.
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inhibited in Elk-1 signaling by FTI to a similar extent as was
H-Ras despite an incomplete shift in gel mobility (Fig. 2) sug-
gests that the unprocessed population of this construct might
be acting as a dominant negative inhibitor for signaling
through the remaining prenylated protein. This dominant neg-
ative effect would result from the sequestration of effector
proteins such as Raf that bind unprenylated Ras, which itself
remains cytosolic, and suggests that complete inactivation of
FTase by FTIs may not be necessary for effective cancer treat-
ment (27).
All alternatively geranylgeranylated M-CAAX-containing
constructs evaluated showed a characteristic increase in Ras
signaling through Elk-1 with increasing FTI concentration. A
similar phenomenon has been reported previously with signal-
ing to Elk-1 and c-Jun (28). In our assay, FTI-induced increases
in Elk-1 activation ranges from 20 to 100% over untreated
control cells and occurs even when nonnative M-CAAX motifs
replace native versions. In contrast, two constructs that lack an
M-CAAX but contain a polybasic domain (H-(K6) and N-(K6)-
CVLS) show a flattened FTI response, indicating neither a
decrease nor an increase in signaling in response to FTI. This
suggests that geranylgeranylation of Ras proteins increases
their signaling capabilities. Although it is not clear why this
might be the case, it is possible that geranylgeranylation tar-
gets Ras to different membrane subdomains than does farnes-
ylation, bringing it into closer proximity with effector proteins.
The demonstration that the Ras prenyl group is involved in
effector association and activation (29) supports the possibility
that geranylgeranylated Ras more effectively activates effec-
tors through enhanced association. An FTI-induced increase in
Ras signaling via Elk-1 cannot be the result of inhibition of
other farnesylated proteins that might normally inhibit Ras
function or else all Ras constructs would be similarly affected,
but H-Ras, N-(K6)-CVLS, and K-(Q5)-CVLS are not. Interest-
ingly, this phenomenon also occurs with K-CVLS although this
protein is not geranylgeranylated. When the polybasic domain
is then removed (K-(Q5)-CVLS), this increase is reversed (albeit
to a lesser extent that that seen with H-Ras and N-CVLS),
suggesting once again that the polybasic domain confers FTI
resistance. That this resistance is greater in K-Ras4B than in
H-Ras or N-Ras may result from the contribution of other
sequence elements unique to K-Ras4B. However, this FTI-
induced increase in Elk-1 reporter activation does not appear to
correlate with transforming activity, which is independent of
the specific isoprenoid modification of Ras (30).
The Polybasic Domain Confers FTI Resistance on Ras-in-
duced Anchorage-independent Growth—Although we had dem-
onstrated the independent roles of the polybasic domain and
the CAAX motif in functional FTI resistance with respect to
Ras prenylation and Ras signaling, we could not conclude that
these data would reflect Ras function in vivo with respect to a
more complex aspect of the transformed phenotype such as
anchorage-independent growth. In order to address the func-
tional significance of the polybasic domain and/or the CAAX
motif in transformation, we stably transfected NIH 3T3 fibro-
blasts with several activated Ras mutants and assessed their
ability to form colonies in soft agar in the presence or absence
of FTI.
As shown in Fig. 4, NIH 3T3 cells expressing all of the
activated Ras constructs were able to generate colonies in soft
agar in the absence of FTI. In the three activated Ras con-
structs that lacked both the polybasic domain and an M-CAAX
motif (H-Ras, N-CVLS, K-(Q5)-CVLS), colony growth was in-
hibited by 10 M FTI to approximately the same degree (87,
100, and 94%, respectively), suggesting that at least one of
these motifs is necessary for functional Ras FTI resistance.
The H- and N-Ras constructs assayed consistently support
the assertion that either a polybasic domain or an M-CAAX
motif confers some functional FTI resistance on Ras proteins.
Both H-CVIM and H-(K6) (24 and 34% block at 10 M FTI,
respectively), each of which contains one of the motifs, show
approximately the same increase in FTI resistance as com-
pared with H-Ras (87% block). When both motifs are simulta-
neously placed into H-Ras, functional FTI sensitivity is elimi-
nated, suggesting that the individual contributions of each
motif to FTI resistance are additive. Similarly, whereas N-
CVLS (which contains neither motif) is highly sensitive to FTI
(100% block at 10 M FTI), N-Ras constructs containing either
motif (N-Ras or N-(K6)-CVLS) are significantly less sensitive to
FTI treatment (40 and 40% blocks at 10 M FTI). Also, the
addition of an M-CAAX motif to the FTI-sensitive K-(Q5)-CVLS
construct (94% block at 10 M FTI) reduces the effect of FTI to
approximately the same degree (K-Ras6KCVLS; 31% block at
10 M FTI) as it does in the corresponding H- and N-Ras
constructs (H-(K6), 34% block at 10 M FTI; N-(K6)-CVLS, 40%
block at 10 M FTI). Together, these data indicate that either a
polybasic domain or an M-CAAX motif can render Ras proteins
less sensitive to FTI-induced functional inhibition but that
FIG. 4. The polybasic domain confers FTI resistance on Ras-induced anchorage-independent growth. NIH 3T3 fibroblasts stably
transfected with active Ras mutant constructs were plated in 0.4% agar in the presence of FTI L-744,832 and maintained for 14 days. The
percentage of cells forming colonies in soft agar in the presence of FTI is expressed in comparison with the percentage of vehicle-treated cells
forming colonies. Solid bars, vehicle (Me2SO); dark gray bars, 3 M FTI; light gray bars, 10 M FTI.
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both may be necessary for maximum functional resistance.
However, the anchorage-independent growth data for K-Ras
and K-CVLS are not consistent with this model. Although
K-Ras contains both motifs, it shows significant FTI sensitivity
(53% block at 10 M FTI), which contrasts sharply with H-(K6)-
CVIM (0% block at 10 M FTI), which also contains both motifs.
And although K-CVLS (79% block at 10 M FTI) predictably
shows greater FTI sensitivity than K-Ras (53% block at 10 M
FTI), it unexpectedly shows considerably greater FTI sensitiv-
ity than the corresponding H-(K6) (34% block at 10 M FTI).
These differences may result from functional differences be-
tween H-Ras and K-Ras4B that are unrelated to prenylation.
Several lines of evidence have suggested that H-Ras and
K-Ras4B are functionally distinct, possibly related to their
different microlocalization (31–34). If this is the case, K-Ras4B-
induced soft agar colony growth may depend more strongly on
the function of other farnesylated proteins (35, 36) that are
themselves sensitive to FTI, whereas H-Ras-induced colony
growth may rely less on other farnesylated proteins. The ob-
servations that the Ras mutation status of cells does not cor-
relate with FTI sensitivity and that other farnesylated, Ras-
related proteins are necessary for Ras transformation (37)
supports this hypothesis. Our data show that the signaling
pathway(s) used by K-Ras4B to induce soft agar colony growth
is sensitive to FTI although K-Ras4B itself is FTI-resistant.
Further, we show that an FTI-resistant mutant of H-Ras (H-
(K6)-CVIM) can induce colony growth that is not inhibited by
FTI, indicating that H-Ras and K-Ras4B may induce transfor-
mation by mechanisms that do not overlap completely.
The Polybasic Domain Increases Ras Affinity for FTase—The
results of our prenylation assays, soft agar assays, and lucifer-
ase assays demonstrated the independent role of the polybasic
domain in conferring on Ras proteins functional resistance to
FTI. However, each of these assays was performed in tran-
siently or stably transfected cells in which FTI resistance could
result from increased Ras affinity for FTase and/or alternative
prenylation. Therefore, it was not clear whether, in the absence
of alternative prenylation, the M-CAAX motif would itself con-
tribute to increased Ras affinity for FTase or whether this role
was exclusive to the polybasic domain. Although James et al.
(20) had shown that an M-CAAX (-CVIM) or a polybasic domain
each increased affinity of H-Ras (H-CVIM) for FTase by 6-
fold, these increases in affinity unexpectedly did not result
in increased resistance to the benzodiazepine peptidomimetic
FTI, BZA-2B.
To clarify this point, we assessed the affinity of several Ras
mutants for FTase by in vitro prenylation assays. Bacterially
expressed Ras mutants, which are unprenylated due to the
absence of FTase in E. coli, were isolated and used as sub-
strates in a reaction also containing [3H]farnesyl pyrophos-
phate and purified FTase. The prenylation of each substrate
protein was performed in the presence of a peptide-competitive
FTI (L-744,832) at several concentrations in order to determine
the FTI concentration at which 50% of the maximal prenylation
reaction could be inhibited (IC50). The results of these assays
are summarized in Table I. Together, the polybasic domain
(6K) and an M-CAAX (-CVIM) render either H-Ras (H-(K6)-
CVIM) or K-Ras resistant to FTI at all concentrations tested
(IC50  625 nM), confirming that these motifs in combination
contribute to Ras affinity for FTase and account for the FTI
resistance of K-Ras4B. However, replacement of the polybasic
domain with five consecutive glutamines (K-(Q5); IC50  80 nM)
while keeping the CVIM sequence intact reduces the Ras/
FTase association to levels approximating that of H-Ras
(IC50  10 nM). Based on the crystal structure of FTase com-
plexed with a K-Ras4B CAAX peptide and a farnesyl diphos-
phate analogue (38), it seems likely that increased affinity
between FTase and Ras results from the ionic interaction of the
Ras polybasic domain and an acidic region on the surface of
FTase near the active site. Residual physical association be-
tween K-(Q5) and FTase probably results from hydrogen-bond-
ing interactions between the polar glutamine residues and this
negatively charged region of FTase. If the corresponding se-
quence of H-Ras is substituted for the glutamines, affinity is
reduced further (K-(H); IC50  25 nM), showing that the poly-
basic domain alone accounts for most of the affinity of Ras for
FTase. The subsequent removal of the CVIM from K-(H) to give
K-(H)-CVLS (IC50  20 nM) has no additional effect on associ-
ation with FTase, further confirming that the M-CAAX motif
does not significantly contribute to the Ras/FTase interaction.
Alternative Prenylation of N- or K-Ras Is Functionally Tol-
erated—Finally, in light of evidence that the identity of the
prenyl group may influence signaling and/or subcellular local-
ization of Ras (29, 39, 40), we wanted to confirm the functional
equivalence of farnesylated and geranylgeranylated Ras. If
Ras-F and Ras-GG do not have identical functions in cellular
signaling, then the well established effect of FTIs on K-Ras-
transformed cells may result from this difference rather than
(or in addition to) FTI inhibition of non-Ras farnesylated pro-
teins. In order to rule out the former possibility, we first con-
firmed the ability of alternatively prenylated wild-type N- and
K-Ras (N-Ras-GG and K-Ras-GG) to support the growth of NIH
3T3 cells (Fig. 5). Our observations that N- and K-Ras support
cell growth when alternatively prenylated support the current
belief that FTI-induced geranylgeranylation of N- and K-Ras
has no discernible effect on their function, is tolerated by cells,
and permits these Ras isoforms to protect normal cells from
FTI toxicity. That wild-type H-Ras-GG fails to support cell
growth contrasts with the ability of the oncogenic H-Ras-GG
mutants that we tested to generate stable NIH 3T3 cell lines
and induce anchorage-independent growth (Fig. 4). This sharp
functional distinction in proliferation may reflect the observa-
tion that inactive and active H-Ras have been shown to parti-
tion into distinct plasma membrane microdomains with dis-
tinct functional consequences (39, 40).
To further confirm the functional equivalence of farnesylated
and geranylgeranylated K-Ras, we compared the gene expres-
sion profiles of transformed human embryonic kidney cells
(HEKs), stably expressing the oncogenic form of either K-Ras-F
or K-Ras-GG, by microarray analysis on arrays containing
18,000 human genes and expressed sequence tags (University
of North Carolina Lineberger Comprehensive Cancer Center,
TABLE I
The polybasic domain increases Ras affinity for FTase
In vitro prenylation reactions containing bacterially expressed, un-
prenylated Ras proteins (1 M), [3H]farnesyl pyrophosphate (1 M), and
purified recombinant FTase (50ng) were performed in the presence of
various FTI concentrations (5-625 M) or vehicle (Me2SO) for 10 min at
30 °C. Proteins were precipitated with trichloroacetic acid, immobilized
on membranes, and washed free of unreacted radiolabel. Incorporation
of [3H]farnesyl into protein was determined by scintillation counting
and normalized to maximal incorporation determined in the absence of
FTI and allowing the reaction to go to completion. The concentration of
substrate-competitive FTI necessary to block 50% of maximal farnes-
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Genomics Core Facility). We observed no significant differences
at the mRNA level between the set of genes expressed in either
cell line (data not shown), suggesting that signaling by K-Ras is
independent of the identity of the prenyl group. This is consist-
ent with reports in which RhoA signaling was shown to be
independent of the identity of the prenyl group (41, 42). We
conclude that K-Ras-F and K-Ras-GG are functionally equiva-
lent and that the effect of FTIs on K-Ras-transformed cells
probably results from inhibition of other farnesylated proteins.
Therefore, it is especially important to identify unambiguously,
as we have helped to do here, the sequence elements in
K-Ras4B that render it resistant to FTI, in order to define
criteria by which other relevant FTIs targets may be identified.
DISCUSSION
Our studies demonstrate a previously unreported contribu-
tion of the polybasic domain characteristic of K-Ras4B to the
functional resistance of Ras proteins to FTIs independent of
M-CAAX-induced alternative prenylation. Either motif alone,
when placed into H-Ras, prevents FTI-induced inhibition of
prenylation, reduces the sensitivity of Ras-transformed NIH
3T3 fibroblasts to FTI-induced inhibition of anchorage-inde-
pendent growth, and prevents FTI-induced block of Ras-de-
pendent signaling through the transcription factor Elk-1. We
have also shown that this effect is the result of enhanced
physical association between FTase and Ras mediated by the
polybasic domain. We propose a model in which a methionine-
containing CAAX motif allows Ras to bypass FTI-induced func-
tional inhibition by permitting alternative prenylation of Ras
proteins by GGTase, and the polybasic domain renders FTIs
less effective as competitive inhibitors by increasing Ras affin-
ity for FTase.
These results may have important implications for the iden-
tification of relevant FTI targets that may include both Ras and
non-Ras farnesylated proteins. There are 250 human pro-
teins with literal carboxyl-terminal CAAX motifs. However,
most of these contain amino acids at the -AAX positions that
make them poor substrates for FTase (43–45). Of those that
are potential FTase substrates (Table II), many, including nu-
merous members of the Ras superfamily, are known to be
farnesylated, whereas others are presumed to be farnesylated
but have not yet been specifically evaluated. At present, several
CAAX-containing, farnesylated human proteins are currently
under investigation as FTI targets (reviewed in Refs. 3, 5, 6, 13,
and 46), including RhoB, the centromere-binding proteins
CENP-E and CENP-F, the phosphatases PRL1, -2, and -3, the
chaperone protein DnaJ, and Rheb. Our data demonstrating
the importance of the polybasic domain in FTI resistance sup-
port the possibility that these proteins, which lack a polybasic
domain, should be sensitive to FTIs and may account for the
effects of FTIs on transformed cells in vitro and in vivo. Indeed,
Rheb has been shown to be FTI-sensitive (47, 48) and appears
not to be subject to alternative prenylation (48). PRL1 to -3 are
possible exceptions, since each contains either two or three
basic amino acids just upstream of the CAAX motif. However,
it is not clear from our studies whether three basic amino acids
can confer FTI resistance to the same degree as the polybasic
domain of K-Ras4B that contains six consecutive basic
amino acids.
Among those farnesylated proteins not yet under intensive
study, we predict that the absence of a polybasic domain in
RhoD, inositol-1,4,5-trisphosphate 5-phosphatase IV, and
Rap2A would render these proteins FTI-sensitive. In contrast,
the presence of basic amino acids in Rnd1, Rnd2, Rnd3/RhoE,
TC10, and inositol-1,4,5-trisphosphate 5-phosphatase I might
impart significant FTI resistance to these proteins.
Similar predictions can be made for CAAX-containing pro-
teins whose prenylation status has not yet been explicitly de-
termined but whose CAAX sequences and homology to other
farnesylated proteins imply that they too will be farnesylated.
For example, the putative tumor suppressor NOEY2/ARHI/
RhoI, which lacks a polybasic motif, is more likely to be FTI-
sensitive than AGS1, which contains three basic amino acids.
In addition, a search of the SwissProt database shows that
there are 40 other human proteins unrelated to the Ras
superfamily whose CAAX motifs could support farnesylation.
Among these are cyclin G2 (CFPS), members of the transform-
ing growth factor  (CKCS), inhibin (CGCS), and bone morpho-
genetic protein (CGCH) families, many of which lack a polyba-
sic domain, making them potential FTI targets if they are
farnesylated. Given the current confusion surrounding the
identity of relevant FTI targets, it will be important to deter-
mine whether any of these proteins is farnesylated, affected by
FTIs, and can account for the observed biological effects of
FTIs. In any case, it is likely that FTIs will affect numerous
farnesylated proteins simultaneously to produce complex, cell
type-specific effects.
Complicating the identification of relevant FTI targets is the
potential alternative geranylgeranylation of M-CAAX proteins
in the presence of FTI. This phenomenon, well documented
here and elsewhere for N-Ras (CVVM) and K-Ras (CVIM) (8, 9,
21), may also apply to other farnesylated proteins such as RhoE
(CTVM) to render these proteins FTI-resistant regardless of
the presence or absence of a polybasic motif. There is also
evidence implicating the prenyl group in the association of Ras
family proteins with both downstream effectors (29) and up-
stream guanine nucleotide exchange factors (49), suggesting
that geranylgeranylated proteins may not always be function-
ally equivalent to their farnesylated counterparts and, there-
fore, that alternatively prenylated proteins including N-Ras
and K-Ras may be relevant FTI targets. However, our obser-
vation that both farnesylated and geranylgeranylated
K-Ras12V produce nearly identical gene expression profiles
when stably expressed in human embryonic kidney cells sup-
ports the widely held belief in the functional equivalence of the
farnesylated and geranylgeranylated forms of this protein and
clearly implicates other farnesylated proteins in the inhibition
of K-Ras-transformed cells by FTIs.
Many proteins that are normally geranylgeranylated, such
as members of the Rho family, also contain polybasic domains.
FIG. 5. Alternative prenylation of N- and K-Ras is functionally
tolerated. NIH 3T3 cells were transfected with wild-type N-Ras, K-
Ras, or H-Ras modified to be preferentially geranylgeranylated (188/
189L) or with empty vector (pZIP). Transfected cells were selected in
400 g/ml G418, and colonies were stained with crystal violet.
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This observation is of particular interest in light of the fact that
the negatively charged surface of FTase with which the poly-
basic domain interacts resides primarily within the -subunit
of the enzyme (38) that is common to both FTase and GGTase.
Therefore, geranylgeranylated proteins that contain polybasic
domains may be more resistant to Ras-competitive GGTIs than
those that do not, suggesting that these proteins can also be
usefully defined according to the presence or absence of a
polybasic domain.
Previously, in vitro studies using purified FTase and Ras
substrates showed that neither an M-CAAX nor a polybasic
domain increase FTase resistance to the peptidomimetic FTI
benzodiazepine (20). However, since FTIs such as L-744,832
compete with substrate for binding to enzyme, it seemed likely
that if the polybasic domain increases Ras affinity for FTase, it
alone should contribute to functional FTI resistance in Ras
proteins. Our work confirms this possibility by showing that a
polybasic domain alone is sufficient to render Ras partially
functionally resistant to the FTI L-744,832, as demonstrated by
the ability of polybasic domain-containing Ras mutants to pro-
duce colonies in soft agar and to signal through the transcrip-
tion factor Elk-1 in the presence of FTI. Moreover, we have
shown that this resistance is probably the result of increased
affinity of Ras for FTase. This conclusion is consistent with
previous reports (21, 50) that have shown that K-Ras4B has an
affinity for FTase 10-fold greater than N-Ras and 20-fold
greater than H-Ras, suggesting that the M-CAAX motif does
not contribute greatly to Ras affinity for FTase, whereas the
polybasic domain of K-Ras4B does.
Our observation that anchorage-independent growth of NIH
3T3 cells stably expressing K-Ras4B is partially sensitive to
FTI although this Ras isoform contains both a methionine-
containing CAAX motif and a polybasic domain, becomes alter-
natively prenylated, and signals efficiently through Elk-1 in
the presence of FTI suggests that H-Ras and K-Ras4B are
functionally distinct, a hypothesis for which considerable evi-
TABLE II
Farnesylated proteins can be distinguished by the presence or absence of a polybasic domain
Human proteins containing a CAAX motif were compiled from the SwissProt database. Those with CAAX motifs containing amino acids that
presumably preclude farnesylation and those in which X represents leucine (L, coding for geranylgeranylation) were eliminated. For each protein,
the CAAX sequence and the sequence immediately upstream of the CAAX motif corresponding to the polybasic domain of K-Ras4B are shown. The
accession numbers can be used to search the “protein” database at the Web site for the National Center for Biotechnology Information
(www.ncbi.nlm.nih.gov). *, an accession number for the “nucleotide” database. ND, prenylation has not been explicitly reported. Proteins are
grouped according to current knowledge concerning their potential for alternative prenylation and their relevancy as FTI targets and are listed
alphabetically within each group.
Protein name Accession no. “Polybasic” region CAAX Alt Pren?
Farnesylated proteins under evaluation as potential
FTI targets
CENP-E CENE_HUMAN HASSGKDVPE CKTQ N
CENP-F CENF_HUMAN AGLESKGSEN CKVQ N
DnaJ DJA1_HUMAN EDDEHHPRGGVQ CQTS N
H-Ras RASH_HUMAN DESGPGCMSCK CVLS N
PRL-1 (PTPCAAX1) NP_003454 KDSNGHRNN CCIQ N
PRL-2 (PTPCAAX2/OV-1) NP_003470 RFRDTNGH CCVQ N
PRL-3 NP_116000 KDPHTHKTR CCVM ?
Rheb RHEB_HUMAN DGAASQGKSS CSVM N
RhoB RHOB_HUMAN KRYGSQNGCINC CKVL Both
Confirmed or likely farnesylated proteins
AGS1 (activator of G-protein signaling) NP_057168 SQAKDKER CVIS ?
G-protein, 11 subunit GBGB_HUMAN DKNPFKEKGS CVIS N
G-protein, -T1 subunit (transducin) GBG1_HUMAN EDKNPFKELKGG CVIS N
G-protein, -T2 subunit GBGU_HUMAN DKNPFKEKGG CLIS N
G-protein-coupled receptor (putative) GP41_HUMAN QGCGTGGQVA CAES N
Inositol-1,4,5-trisphosphate 5-phosphatase I I5P1_HUMAN GKPHAHVHKC CVVQ N
Inositol-1,4,5-trisphosphate 5-phosphatase IV *AF187891 QQALQSQNSSTI CSVS N
Lamin A/C LAMA_HUMAN SSPRTQSPQN CSIM ?
Lamin B1 LAM1_HUMAN QGTPRASNRS CAIM ?
Lamin B2 LAM2_HUMAN QGDPRTTSRG CYVM ?
K-Ras4A RASK_HUMAN KTPCGVKIKK CIIM Y
K-Ras4B RASL_HUMAN KKKKKKSKTK CVIM Y
NOEY2/ARHI/RhoI RHOI_HUMAN MPNTTEKLLDK CIIM ?
N-Ras RASN_HUMAN DGTQGCMGLP CVVM Y
Phosphorylase B kinase  subunit KPB1_HUMAN YVQEFLPHSI CAMQ ?
Phosphorylase B kinase  subunit KPBB_HUMAN EGEVKPNNDDP CLIS ?
Peroxisomal farnesylated protein (PXF/HK33) PXF_HUMAN SGPPGASGEQ CLIM ?
Rap2A RAP2_HUMAN DKDDPCCCSA CNIQ N
RhoD RHOD_HUMAN WRRITQGF CVVT N
Rhodopsin kinase RK_HUMAN GSSSSSKSGM CLVS N
Rnd1 (Rho6) RHO6_HUMAN TFKKEKAKS CSIM ?
Rnd2(RhoN/Rho7) RHON_HUMAN EIHKDRAKS CNLM ?
Rnd3(RhoE/Rho8) RHOE_HUMAN TDLRKDKAKS CTVM ?
TC10 NP_036381 KRIGSRCINC CLIT N
Unknown prenylation status
Bone morphogenetic protein 5-8 precursors BMP5(6,7,8)_HUMAN K/RKY/HRNMVVRA CGCH ND
Bone morphogenetic protein 11 precursor GDFB_HUMAN YGKIPGMVVDR CGCS ND
Cyclin G2 CGG2_HUMAN FFFNFKVAQTL CFPS ND
Inhibin  a-(c-, e-) chain precursor IHBA(C,E)_HUMAN K/TDI/VQ/PN/DMI/VVEE/A CGCS ND
MAPKAP kinase-2 AAD09136 NKRRKKQAQSSSASQG CNNQ ND
Neuropeptide Y receptor type 5 NY5R_HUMAN IKADLVSLIH CLHM ND
Phosphorylase B kinase -liver KPB2_HUMAN YLQELLPNSG CQMQ ND
Serine/threonine protein kinase 11 ST11_HUMAN SSKIRRLSA CKQQ ND
TGF1 (2, 3) precursor TGF1(2, 3)_HUMAN EQLSNMI/VVRS CKCS ND
WNT-3A WN3A_HUMAN NARAERRREK CRCV ND
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dence has accumulated (31–34, 51). In our studies, K-Ras and
H-(K6)-CVIM appear to induce anchorage-independent growth
via incompletely overlapping mechanisms that are not equally
affected by FTI. The fact that H-(K6)-CVIM and K-Ras both
activate Elk to the same degree in the presence of FTI while
generating anchorage-independent colonies that are not
equally sensitive to FTI further supports the notion that each
Ras isoform utilizes additional, distinct signaling pathways in
order to produce a transformed phenotype. These pathways
may themselves differentially utilize other farnesylated pro-
teins potentially adding still more complexity. However, since
H- and K-Ras4B have identical effector binding domains but
highly variant COOH termini, differences in preferred signal-
ing pathways may also result from FTI-sensitive differences in
the subcellular localization of each Ras isoform (32, 34, 40, 52).
It is interesting to note that we have created an unnatural Ras
protein (H-(K6)-CVIM) that is more functionally resistant to
FTI at inducing anchorage-independent growth than any nat-
urally occurring Ras variant. It is increasingly likely that bio-
logical differences among the Ras isoforms reflect, in part,
differences in subcellular localization and trafficking mediated
by the divergent COOH termini of these proteins. If this is the
case, studies comparing the signaling mechanisms of K-Ras4B
and H-(K6)-CVIM, which may be similarly modified and local-
ized within the cell, will help distinguish inherent differences
in utilization of signaling pathways from differences in subcel-
lular localization.
Several physical and biological characteristics of K-Ras4B
have been shown to be dependent on the polybasic domain. The
polybasic domain has been shown to be required for 1) K-Ras4B
to transform NIH 3T3 and Rat-1 cells (53), 2) K-Ras4B mem-
brane localization (33), 3) formation of ionic interactions be-
tween the polybasic domain and membrane anionic lipids to
stabilize membrane association (33, 54), and 4) K-Ras4B asso-
ciation with microtubules (55), an interaction that has impli-
cations for differential subcellular transport and localization of
Ras isoforms. Our work adds a new function to this list by
demonstrating the role of the polybasic domain in increasing
Ras affinity for FTase, thereby resulting in enhanced func-
tional Ras FTI resistance and suggesting that FTase may dis-
tinguish among Ras proteins in part through the polybasic
domain.
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